Teva Pharmaceutical Industries Limited

Ruth Tenengauzer

Julia Hrakovsky

Judith Aronhime

Minutza Leibovici

Claude Singer

Tamar Nidam

Marioara Mendelovici

Joseph Schwarz

Michael Pesachovich

Marco Kordova

Mira Kopel

Michal Agami

Ronen Borochovitch

Lev Khondo

Alla Ioffe

Tania Lessen

Eleonora Moin-Kotliar

Mathi Mathivanan

Grigory Bogomolny

Yehudit Dolitsky

The invention encompasses wet granulation pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the wet granulation pharmaceutical composition.

Wet formulations of aripiprazole

The present invention provides pharmaceutical compositions comprising aliphatic amine polymers such as for example Sevelamer HCl as the active pharmaceutical ingredient, wherein the aliphatica amine polymers are spray granulated. The present invention further provides methods of preparing stable pharmaceutical compositions of aliphatic amine polymers such as for example Sevelamer HCl, preferably in tablets dosage forms.

Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture

The present invention encompasses a method of evaluating pharmaceutical compositions of meloxicam whereby one can correlate in vitro properties to in vivo properties, and pharmaceutical compositions developed using the method.

Pharmaceutical compositions comprising meloxicam and methods of their preparation

Provided are processes for preparation of crystalline sertraline hydrochloride Form II substantilly free of other polymorphic forms of sertraline hydrochloride, preferably on an industrial scale.

Processes for preparation of polymorphic form II of sertraline hydrochloride

Compositions and methods of stabilizing azithromycin compositions are described. Stabilized azithromycin compositions comprise an intimate admixture of azithromycin and a stabilizing-effective amount of an antioxidant to improve the resistance of the azithromycin to degradation. Coprecipitation or co-milling of azithromycin and an antioxidant are particularly preferred means of achieving an intimate admixture. Pharmaceutical formulations comprising a stabilized azithromycin composition and methods of making such formulations are also described.

Stabilized azithromycin compositions

A formulation and a method for manufacturing pergolide mesylate is disclosed whereby substantially stable pergolide mesylate can be manufactured without having to introduce stabilizing additives.

Stable pergolide mesylate and process for making same

Novel, stable pharmaceutical formulations for the oral administration of high purity torsemide modification II are disclosed. These formulations release high purity torsemide modification II in water at a constant and high purity rate, and the high purity torsemide modification II therein does not rearrange to torsemide modification I over time. Methods for their manufacture are also disclosed.

Stable pharmaceutical formulation comprising torsemide modification II

Growing community of inventors

Raanana, Israel

Ruth Tenengauzer